We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Adocia Launches Phase IIa Clinical Study on Type 1 Diabetic Patients with its Fast-acting Human Insulin, HinsBet®

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Adocia Launches Phase IIa Clinical Study on Type 1 Diabetic Patients with its Fast-acting Human Insulin, HinsBet®"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Adocia SAS, has announced the launch of its second clinical trial for the development of HinsBet®, its fast-acting human insulin.

The company completed a Phase I study in March on healthy volunteers showing that the action of HinsBet® is as fast as that of NovoLog® and has less variability.

The positive clinical results obtained with HinsBet® during the Phase I study have permitted to quickly start a second study of Phase IIa on 20 type 1 diabetics.

The Phase IIa study is double-blinded, under euglycemic clamp, and aims to compare variabilities of HinsBet® and NovoLog® with three repeated injections of each product to each patient.

“We expect this study to confirm HinsBet®’s similar efficacy on type 1 diabetics compared with Novo Nordisk’s fast-acting insulin analog which is the market leader,” said Dr Gérard Soula, president and CEO at Adocia.

Adocia has developed HinsBet® using its BioChaperone® library of polysaccharides modified with naturally occurring molecules.

BioChaperone® is designed to form a reversible molecular complex with therapeutic proteins in order to solubilize and stabilize these proteins and to control their delivery.

”Adocia’s BioChaperone boosts absorption of insulins, human as well as analogs,” said Dr Olivier Soula, vice president and R&D director at Adocia.

Soula added, “This has already been proved in the clinic in humans with human insulin. Moreover, the absorption rate with NovoLog® has been doubled after subcutaneous injection using a pig model.”

As a result of the promising clinical development, the company is actively seeking pharmaceutical partners in order to develop its innovative insulin formulations.